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ABSTFWCT 
We compared the uptake, metabolism, and biological effects of 
tetraiodothyroacetic acid (Tetrac) and rTs in anterior pituitary cells 
with those of Tb and Ts. Cells were isolated from adult male Wistar 
rats and cultured for 3 days in medium with 10% fetal calf serum. 
Uptake was measured at 37 C in medium with 0.1% BSAfor [“‘IlTet- 
rai (200,000 cpm; 240 pM) and [ 1z511Tb (100,000 cpm; 175 PM) or with 
0.5% BSAfor r’2511rTq (100.000 cnm: 250 DM) and 112511TQ (50.000 cnm: 
50 PM). The f&e fGac;on oiTet& ias 1% that ONTO (&&ed&m iitg 
0.1 and with 0.5% BSA), and the free fraction of rTs was half that of 
Ts. Uptake of the four tracers increased sharply up to 1 h of incubation 
and then leveled off. Expressed as femtomoles per pM free hormone, 
uptake at equilibrium was 1.16 ? 0.16 (n = 6) for Tetrac, 0.15 2 0.01 
(n = 6) for Ta, 0.023 ? 0.003 (n = 6) for rTs, and 0.21 ? 0.02 (n = 6) 
for Ts. Cell-associated radioactivity after incubation for 24 h with 
[1251]Tetrac was represented for 15% by [1251]Triac; after incubation 
with F’IlT~ for 15-20% bv 112511T*. after incubation with r12511rT- for 
6% bj [1z’Il?l,3’-Tz, while r1’511?s Gas still for 98% [1z511Ti. E&o&e 
of cells for 2 h to 100 nM TRH stimulated TSH release by 90-135%. 
Tetrac was effective in reducing this response at a free concentration 
of 0.05 pM, but rTs was effective only at a free concentration of 16 IIM. 
A free Tetrac concentration of 5 pM was equally effective as 50 pM free 
Ta in reducing the TSH response to TRH. In human serum, Tetrac was 
exclusively bound to TG-binding prealbumin. The free Tetrac fraction 
was 0.001~~ in control subjects and rose 2- to 12-fold in patients with 
nonthyroidal illness. As uptake of [ 1251]Tetrac in the pituitary was 
higher than that of Td and Ts, and it was more potent than Td in 
reducing TSH release, Tetrac may be of potential significance for the 
regulation of TSH secretion in ui~o. (EndocrinoZogy 13ti 4454-4461, 
1995) 
N ONTHYROIDAL illness (NTI) and fasting are charac- terized by a low serum Ts concentration and an el- 
evated serum concentration of rTs, whereas the serum Th 
concentration is normal or eventually decreased (l-4). In the 
face of the low serum Ts and Td concentrations, the serum 
TSH level is inappropriately low (1, 2, 4, 5). 
Recently, it was proposed that changes in T4 metabolism 
during fasting and NTI, i.e. a shift from deiodination to 
increased conjugation or alanine side-chain alteration, may 
result in metabolites with a TSH-suppressing effect. The first 
to be evaluated was Ts sulfate (6), but this metabolite ap- 
peared to be biologically inactive at the pituitary level (7,8), 
perhaps because it does not enter the tissue (8). The second 
to be tested was the acetic acid derivative of Ts, triiodothy- 
roacetic acid (Triac) (9,101, which is rapidly taken up by the 
pituitary (11) and has a profound TSH-suppressing effect 
both irz vitro (11,12) and in viuo (13,14). Like Triac, the acetic 
acid derivative of Te, tetraiodothyroacetic acid (Tetrac), was 
suggested to contribute to the suppression of TSH secretion 
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during fasting and NT1 (10). Administration of Tetrac re- 
duced the TSH response to TRH in euthyroid subjects (13). 
Furthermore, in fasting subjects, the serum Tetrac concen- 
tration was reported to increase 2-fold (15). 
Although rTZ is not ascribed any biological activity, recent 
studies indicate that one of its metabolites 3,3’-diiodothyro- 
nine (3,3’-TJ stimulates the mitochondrial respiratory rate 
(16). A similar action has been reported for 3,5-T* (a product 
of Ts deiodination) (16, 17), which, in addition, has been 
shown to suppress TSH secretion in rats (18). The pituitary 
contains the enzyme that deiodinates rTs (19), but before this 
can occur, rTs has to enter the pituitary cells. 
The present study was undertaken to investigate 11 the 
uptake and metabolism of 1z51-labeled rT3 and Tetrac in cul- 
tured anterior pituitary cells compared to that of 1251-labeled 
Ts and T4; 2) the effects of unlabeled Tetrac and rTs on the 
uptake of [ 1z51]Ts; and 3) the effects of unlabeled Tetrac, rT3, 
3,3’-TZ, and 3,5-TZ on TRH-induced TSH release. Finally, we 
evaluated the distribution of Triac and Tetrac among serum 
proteins as well as the free fraction of Triac and Tetrac in 
serum of control subjects and NT1 patients. 
Materials and Methods 
Materials 
All solutions used for cell isolation and cell culture were obtained 
from GIBCO Europe (Breda, The Netherlands), with the exception of 
human serum albumin (Central Laboratory of the Red Cross Blood 
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Transfusion Service, Amsterdam, The Netherlands), dispase (grade II; 
Boehringer Mannheim, Mannheim, Germany), and fungizone (Bristol- 
Myers Squibb, Woerden, The Netherlands). Culture dishes (48 wells) 
were obtained from Costar (Cambridge, MA). TRH was obtained from 
Hoechst (Frankfurt am Main, Germany). All iodothyronines, 3,5-diiodo- 
thyroacetic acid (3,5-Disc), Tria:, and Tetrac, were obtained from Hen- 
ning Berlin (Berlin, Germany). I’iperazine-?QJ’-bis-]2-ethane sulfonic 
acid] (PIPES), HEPES, PJ,?$-bis-[2-hydroxyethyl]2-aminoethane sulfonic 
acid (Bes), 6-propyl-2thiouracil (I’TU), and BSA (fraction V) were ob- 
tained from Sigma Chemical Co. (St. Louis, MO). [3’,5’-*a51]T4 (1500 
&i/p@, ]3’-i* I]Ts (3070 &i/&, [3’,5’-1z511rTa (1200 pCi/kg), and 
carrier-free Na1251 were purchased from Amersham International (Ay- 
lesbury, UK). HPLC pure [3’-iz511Triac) (2730 &i/kg) and ]3’,5’- 
‘z51]Tetrac (2200 pCi/pg) were prepared from Naiz51 and 3,5-Disc or 
Triac, respectively, using the chloramine-T method followed by puri- 
fication on Sephadex LH-20 (20). Sephadex LH-20 and G-25 were ob- 
tained from I’harmacia (Uppsala, Sweden). All other reagents were of 
the highest purity available. 
Animals 
All experiments were performed using male Wistar rats, weighing 
220-250 g. The animals had free access to food and water and were kept 
in a controlled environment (21 C) with constant day length (12 h). 
Cell culture 
Animals (12-18 for each experiment) were killed between 0900-0930 
h by decapitation. The pituitary glands were removed within 5 min, the 
neurointermediate lobe was discarded, and the anterior lobes were 
collected in calcium- and magnesium-free Hanks’ Balanced Salt Solution 
supplemented with 10 g/liter human serum albumin, penicillin (lo5 
U/liter), fungizone (0.5 mg/liter), and sodium bicarbonate (0.4 g/liter). 
Anterior pituitary cells were dissociated with dispase (final concentra- 
tion, 2.4 X 103 U/liter) for 2 h at 37 C in a shaking incubator. From each 
pituitary, around 1.5 X 106 cells were obtained, and the viability of the 
cells, as determined by trypan blue exclusion, was greater than 90%. 
The cells were cultured at 37 C in a water-jacketed incubator with 5% 
CO* at a density of 500,000 cells/well in 48-well culture dishes. The cells 
had attached to the wells after 2 days of culture. On day 3, the cells were 
used for experiments. The culture medium consisted of Minimal Es- 
sential Medium with Earle’s salts supplemented with nonessential 
amino acids, sodium pyruvate (1 mmoj/liter), 10% fetal calf serum, 
penicillin (lo5 U/liter), fungizone (0.5 mg/liter), L-glutamine (2 mmol/ 
liter), and sodium bicarbonate (2.2 g/liter), pH 7.4 (21-23). 
Cellular uptake of 1251-labeled rT3, T3, Tetrac, and T4 
After removal of the culture medium, cells were preincubated with 
0.5 ml incubation medium for 30 min at 37 C. The incubation medium 
was identical to the culture medium, except that fetal calf serum was 
replaced by 0.5%, O.l%, or 0.01% BSA. After preincubation the medium 
was removed, and incubation (15 min-4 h) was started with 0.25 ml 
medium containing [ iz51]rTa (100,000 cpm; 250 PM), ]‘z511Ts (50,000 cpm; 
50 PM), [‘?]Tb (100,000 cpm; 175 PM), or [i”I]Tetrac (200,000 cpm; 240 
PM). Incubations lasting for more than 1 h were performed at 37 C in 
humidified air with 5% CO*. Incubations of shorter duration took place 
in a 37 C incubation chamber on a rotating device without CO*. There- 
fore, the NaHCOA in the culture medium was replaced by an equimolar 
amount of HEI’ES (8.9 mM), PIPES (10.6 mM), and Bes (11.2 111~). After 
incubation, the medium was removed, and cells were washed with l-ml 
volumes of ice-cold saline to remove tracer not bound to the cells. Cells 
were dissolved in 1 ml 0.1 N NaOH and counted for 12sI activity in a 
16~channel y-counter (NE 1600, Nuclear Enterprises, Edinburgh, Scot- 
land). The amount of iz51-labeled compound taken up was expressed as 
a percentage of the radioactivity added (percent dose). The same pro- 
cedure was applied to the incubations without cells. All results are 
corrected for the amount of radioactivity retained in the wells without 
cells. 
For HI’LC analysis of metabolites, incubations were performed for 24 
h with 2 X lo6 cpm Ta (2 nM), Ta (3.5 nM), rTa (5 nrvi), or Tetrac (2.4 nM). 
Cells were further processed as described above. 
LH-20 chromatography 
Aliquots of the incubation medium and cell extracts were chromato- 
graphed on Sephadex LH-20 (24). Iodide was eluted from the column 
with 4X 1 ml 0.1 N HCl. Subsequently, conjugates were eluted with 8X 
1 ml HZO, and finally, iodothyronines were removed from the column 
with 3X 1 ml 1% NHaOH in ethanol. 
HPLC 
The solvent (1% NHhOH in ethanol) of samples prepurified on Seph- 
adex LH-20 was evaporated under a stream of N, at 50 C. The residue 
was redissolved in the Hl’LC mobile phase and injected onto Chrom- 
suher CR columns (10 X 0.3 cm; Chromuack International, Middelbure, 
?he Netherlands) fitted in a Waters H?‘LC system (Waters Associate;; 
Milford, MA). Isocratic elution was performed with a 53:47 mixture of 
methanol in 0.02 M ammonium acetate (pH 4) at a flow rate of 0.9 ml/min 
for studies of ]iz51JT~ metabolism and with a 60:40 mixture of the same 
solutions at the same flow rate for studies of [‘z51]Tetrac metabolism. The 
latter was performed to speed up elution of the acetic acid derivatives. 
Fractions of 0.3 min were collected and counted for radioactivity. The 
retention times of the four unlabeled reference compounds were deter- 
mined with the two elution mixtures by monitoring the absorbance of 
the eluate at 254 nM (20). The procedure was applied to cell samples as 
well as to the blank samples (without cells) to allow correction for 
degradation of ] 1251]T4 or [iz51]Tetrac during evaporation and HI’LC 
analysis. 
TSH release 
After removal of culture medium, cells were washed once with in- 
cubation medium. The incubation medium was identical to the culture 
medium, except that the fetal calf serum was replaced by 0.5% BSA. 
Pituitary cells were preincubated (0.5 ml) for 2 h at 37 C in a water- 
jacketed incubator with 5% CO2 in the absence or presence of variable 
concentrations (0.01 n&r to 1 FM) of Ta, Te, rTs, Triac, Tetrac, 3,5-T2, or 
3,3’-T2. The preincubation medium was discarded, and fresh incubation 
medium (0.5 ml) was added containing TRH (100 nM) without or with 
the same additions as described above. Incubation was continued for 2 
hat 37 C. This medium was removed, centrifuged (2000 X g), and stored 
at -20 C. TSH in incubation medium was measured by RIA (22). 
Free fractions of iodothyronine derivatives 
The free fractions of iodothvronines, Tetrac and Triac, were deter- 
mined by equilibrium dialysis (25). The free Triac fraction was corrected 
for the fact that around 70% of ]*z511Triac oreciuitated with M&l?. The 
free fractions of all iodothyronines used i; thi;study were determined 
in incubation medium with 0.5% BSA; those of Tetrac and Th were also 
determined in incubation medium with 0.1% BSA. The free fractions of 
Triac and Tetrac were also determined in the serum of five control 
subjects and six NT1 patients. 
Agar gel electrophoresis 
The distribution of Triac and Tetrac among serum binding proteins 
was determined by agar gel electrophoresis (26). The sera (50 ~1) were 
mixed with bromophenol blue (1 ~1) and iz51-labeled Triac or Tetrac (lo6 
cpm). Gels were run for 60 min at 70 mA/slide (-150 V) at 15 C. 
Successive slices of 2 mm gel were counted, and the binding proteins 
Td-binding globulin (TBG), albumin, and Td-binding prealbumin (TBI’A) 
were identified using the bromophenol blue staining of albumin as a 
reference; the region between the origin and albumin contained TBG, 
whereas the region anodal to albumin contained TBI’A. 
Statistics 
The statistical significance of any of the tested compounds on [i?]Ta 
uptake or on TSH secretion was evaluated by Student’s f test or one-way 
analysis of variance and Duncan’s test for multiple comparisons. P < 
0.05 was regarded as statistically significant. 
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Results 
Free fractions of iodothyronine derivatives 
The free fractions of 3,3’-TZ, Ts, rTs, Ta, Triac, and Tetrac 
in medium with 0.5% BSA are shown in Fig. 1. The free 
fraction decreases as the number of iodine atoms in the 
compound increases, whereas a change in the alanine side- 
chain to acetic acid, as in Triac and Tetrac, decreases the free 
fraction by a factor 8 (Triac ZJS. TJ or 100 (Tetrac VS. TJ. The 
free fractions of Tetrac and T* in medium with 0.1% BSA 
amounted to 0.029 ? 0.001% (n = 3) and 3.33 ? 0.08% (n = 
4), respectively, i.e. again a loo-fold difference. The free Ts 
fraction (3.61 2 0.05%; n = 12) did not change after the 
addition of 1 nM-1 &LM Ta, Triac, Tetrac, or rTa, but it increased 
to 4.53 ? 0.13% (n = 4), 4.51% (n = 2), 4.17 * 0.02% (n = 4), 
and 4.43 ? 0.09% (n = 4) after the addition of 10 PM Ta, Triac, 
Tetrac and rTa, respectively. 
Time course of uptake of [1251]rT3 and [12’I]Tetrac 
Figure 2 shows the time course of [iz51]rTs uptake com- 
pared with that of [‘*51]Ts expressed as a percentage of the 
dose (Fig, 2A) or as femtomoles per pM free hormone (Fig. 
2B). The uptake curve for [ *z51]Ts was similar to that previ- 
ously described (11,22), showed a steep phase up to 1 h of 
incubation, and reached equilibrium between l-4 h of in- 
cubation (Fi .2A). At any time point of the experiment, the 
uptake of 1 lg51]rTs was only 3-4% of the uptake of [1z511T3 
(Fig. 2A, Zower curve). When expressed as femtomoles per PM 
free hormone, there was still a large difference between the 
uptake of the two hormones, but as the free fraction of rTa 
was half that of Ta, the values for rTa uptake were about 10% 
of those for Ta uptake (Fig. 2B). 
Similar comparisons were made for the uptake of [lz51]Tet- 
rat and [iz51]T* in incubation medium with 0.1% BSA (Fig. 3). 
Uptake of [1*51]Tb showed a steep phase up to 1 h of incu- 
bation and reached a plateau at 4 h of incubation (Fig. 3A, 
upper curve). Uptake of 11z511Tetrac, expressed as percent 
dose, was less than 0.15% at any time point of the incubation 
(Fig. 3A, Zower curve), and [iz51]Td uptake was about lo-fold 
higher at equilibrium (Fig. 3A, upper curve). However, when 
the data were expressed as femtomoles per PM free hormone, 
the picture was precisely reversed; the maximum uptake of 
[1z51]Tetrac was 1.16 2 0.16 (n = 6) fmol/pM free Tetrac, and 
3,3’-T2 T3 rT3 Trim 
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FIG. 1. Free fraction of iodothyronines and analogs in incubation 
medium with 0.5% BSA. Burs show the mean 2 SE of three to eight 
determinations of the free fraction by equilibrium dialysis. A and B 
differ by a factor of 10 in the scale on the y-axis. 
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FIG. 2. Time course of uptake of [1z511Ta (0) and [lzr’IlrTs (0) in 
cultured anterior pituitary cells expressed as the percent dose (A) or 
as femtomoles per pM free hormone CB). Cells were cultured for 3 days 
at a density of 500,000 cells/well. After preincubation for 30 min in 
incubation medium with 0.5% BSA, cells were incubated for 15 min, 
1 h, or 4 h in the presence of [ “‘IIT~ (50,000 cpm) or 11z511rT~ (100,000 
cpm). Data represent the mean 2 SE of six observations from two 
independent experiments. 
that of [lz51]T4 was 0.15 ? 0.01 (n = 6) fmol/pM free TJ (P < 
0.001; Fig. 3B). 
Metabolism of iodothyronines and Tetrac 
Table 1 shows the presence of iodide and conjugates in the 
incubation medium (first two COI~MZS) and HPLC analysis of 
the cell-associated radioactivity (M four CO~MZQS) after in- 
cubation of pituitary cells with [1z51]Ts, [1z51]Td, and [1z51]rTa 
for 24 h. After incubation with [1251JTs, no iodide was de- 
tectable with only a small amount of conjugates. Further- 
more, almost all cell-associated radioactivity represented 
[1z51]Ts, indicating that Ta is not metabolized in pituitary 
cells. Within the same experiment, however, [1251]TJ was 
metabolized, as shown by the production of iodide in the 
medium and the presence of [“‘I]T3 in the cells, representing 
20% of the cell-associated radioactivity. The conversion of 
[1251]TJ to [1251]Ta was not inhibited by simultaneous incu- 
bation with 100 PM I’TIJ, but was almost completely blocked 
by th;pence of 1 PM unlabeled Td. Finally, incubation 
with [ I]rTs resulted in a significant production of iodide 
and conjugates, whereas about 6% of the cell-associated ra- 
dioactivity represented [1251]TZ. 
The 24-h uptake and metabolism of [1z51]Tetrac were com- 
pared with those of [iz51]Tb (Table 2). To ensure that uptake 
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FIG. 3 Time course of uptake of 1 12511T4 (0) and [1251]Tetrac (0) in 
cultured anterior pituitary cells expressed as the percent dose (A) or 
as femtomoles per PM free hormone (B). Cells were cultured and the 
experiment was performed as described in Fig. 2, except that the 
incubation medium contained 0.1% BSA and [1251]T4 (0.1-2 X 106 
cpm) or 11s511Tetrac (0.2-2 X 106 cpm). Data represent the mean 2 SE 
of six observations from two independent experiments. 
of ]1251]Tetrac was large enough to allow Sephadex LH-20 
chromatography and HPLC, the experiment was carried out 
with 0.01% and 0.1% BSA in the incubation medium. As 
shown in Table 2, about 15% of the cell-associated radioac- 
tivity of ]iz51]Tb and ]iz511Tetrac represented [iz51]Ta and 
[*2511Triac, respectively, after incubation for 24 h under the 
two experimental conditions. Net release of [12511iodide into 
the medium was: in 0.01% BSA, 3.9% (n = 2) from [*251]TJ and 
1.8 2 0.2% (n = 3) from ]12511Tetrac; and in 0.1% BSA, 2.8 ? 
0.3% (n = 3) from [1251]Td and 0.6 ? 0.1% (n = 3) from 
[*2511Tetrac. 
Effects of rTs, Tetrac, and Triac on [1251]T3 uptake 
Due to the very low tracer uptake (percent dose) of 
[1251]Tetrac and ]12511rTa, it was impossible to perform de- 
tailed studies on the effects of thyroid hormone analogs or 
metabolic inhibitors on the plasma membrane uptake of 
these tracers. Therefore, we studied the effects of unlabeled 
Tetrac and Triac on the time course of ]1251]Ta uptake (Fig. 4) 
as well as the effects of unlabeled rTs and Tetrac on the 
15-min uptake of [*251]Ts (Fig. 5). 
The uptake of [1251]Ts was at any time point significantly 
reduced by the presence of 10 FM Tetrac or Triac, and the 
effects of these analogs were similar. The effects of Tetrac and 
Triac were approximately 35%, 45%, and 70% after 15 min, 
1 h, and 4 h of incubation, respectively (all P < 0.001; Fig. 4). 
Measurements of ]12511Ts uptake in the linear part of the 
curve presented in Fig. 4, i.e. after 15 min of incubation, can 
be used to study uptake at the level of the pituitary plasma 
membrane (22, 23). The effects of Tetrac and rTa at concen- 
trations from 1 nM to 1 FM on the 15-min uptake of [1251]Ts 
were compared with those of unlabeled Ta. The effect of 
unlabeled Ta increased progressively with the concentration, 
reaching a maximum of 68% suppression (P < 0.05) at 10 PM. 
In contrast, Tetrac and rTa did not affect [1251]Ts uptake up 
to a concentration of 1 PM, but reduced [1251]Ts uptake by 
about 45% (P < 0.05) at a concentration of 10 PM (Fig. 5). 
Effects on TRH-induced TSH release 
Table 3 shows the effects of Tetrac and rTa compared to 
those of Triac on TSH release during short term exposure to 
TRH. TSH release increased by approximately 90% after 
exposure to 100 nM TRH for 2 h (P < 0.05). This effect was 
SignificantIy reduced by preincubation (2 h) and incubation 
with Triac at a concentration as low as 0.01 nM (71% sup- 
pression; P < 0.05) and was fully blocked at concentrations 
of l-10 nM Triac and higher (P < 0.05). Preincubation and 
incubation with Tetrac resulted in a dose-dependent inhibi- 
tion that was significant at 1 nM, and a maximum (82% 
inhibition; P < 0.05) was seen with a concentration of 1 PM. 
Preincubation and incubation with rTa showed a smaller 
inhibitory effect than that seen with Tetrac. Only at a rTa 
concentration of 1 PM was the TSH response to TRH signif- 
icantly reduced (57%; P < 0.05). A direct comparison be- 
tween Tetrac and Ta in a single experiment showed that 100 
nM Tetrac reduced TRH-induced TSH release to the same 
extent as 10 nM T* (36% and 27% inhibition, respectively; 
Table 4). 
Similarly, the effects of preincubation and incubation with 
3,3’-Tz and 3,5-T2 were compared with those of Ta (Table 5). 
The stimulation during short term exposure to 100 nM TRH 
was 133% (P < 0.05) in these experiments. Preincubation and 
incubation with Ts resulted in a dose-dependent inhibition of 
the TSH response to TRH, which was significant at concen- 
trations of 1 nM and higher. 3,5-T2 reduced the TSH response 
significantly at a dose of 1 nM, and the effect of 100 nM 3,5-T2 
was as great as that of 1 nM Ts (55% suppression; P < 0.05). 
3,3’-T2 showed no inhibitory effect in doses less than 100 nM, 
but this dose had the same effect as 100 nM 3,5-T2 or 1 nM Ts. 
Serum binding and free fraction of Triac and Tetrac 
The binding of Triac and Tetrac to serum proteins was 
determined in four control subjects and four NT1 patients 
(Table 6). In control subjects, Triac was equally bound to 
albumin and TBPA, but in NT1 patients, more Triac was 
bound to albumin than to TBPA. Binding of Triac to TBG was 
negligible in both groups. In contrast, Tetrac was almost 
exclusively bound to TBPA in control subjects. Binding of 
Tetrac to albumin and TBG was about 5%. Also, the binding 
of Tetrac to TBPA was reduced in NT1 patients, whereas 
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TABLE 1. Metabolism of [‘z511Ts, [1z51YI’~, and [1z51]Td in cultured anterior pituitary cells 
Medium (%I Celllllar conhlt (%I 
Iodide Conjugaks pqT 3 [12611T 4 ?IlrT 3 [=‘IlT 2 
[1z511T~ (31 0.0 k 0.0 0.28 2 0.01 98.0 e 0.1 
?IlT~ (6) 1.10 ? 0.04 0.16 2 0.01 21.0 ? 0.6 71.2 2 0.3 
[12511Ta + 100 /AM PTU (3) 1.89 * o.03” 0.16 ? 0.0 21.2 * 0.5 70.9 2 0.9 
~‘=‘IlT~ + 1 /AM Td (3) 0.44 k o.oga 0.32 2 0.02a 1.9 2 o.3” 88.1 ? l.8” 
[‘2511rTX (3) 1.86 * 0.15 2.12 * 0.02 82.4 2 1.0 6.3 2 0.6 
Data represent the mean 2 SE of three to six observations in a single experiment as indicated in parmtheses. Anterior pituitary cells were 
cultured for 3 days at a density of 500,000 cells/well. The cells were preincubated for 30 min in incubation medium containing 0.5% BSA. Then 
they were incubated for 24 h in the same medium containing 2 X 10s cpm of any of the tracers without or with 100 pM PTU or 1 pM Td. After 
incubation, aliquots of the medium and the cells were analyzed by Sephadex LH-20 chromatopaphy. The iodothyronine fraction from the cells 
was further analyzed by HPLC. 
UP < 0.001 us. [‘z511Td alone. 
TABLE 2. Metabolism of [1z51]Td and [“‘IlTetrac in cultured 
anterior pituitary cells 
Sub&rate Uptake (% dose) 
[12’1] activity in cells (%I 
T4 or Tetrac Ts or Triac 
0.01 % BSA 
[1251]Td 5.69 k 0.09 85.2 k 0.8 12.0 k 0.7 
[12511Tetrac 0.35 2 0.08 74.5 2 3.6 15.2 2 1.7 
0.1% BSA 
[‘*‘IIT 2.03 k 0.07 73.1 2 2.5 17.8 2 1.2 
[12511Tetrac 0.16 2 0.01 79.4 2 4.2 12.6 2 0.4 
Data represent the mean ? SE of three observations in a single 
experiment. Anterior pituitary cells were cultured for 3 days at a 
density of 500,000 cells/well. The experiment was performed as de- 
scribed in Table 2 with 2 X 10s cpm [‘z511Td or [12511Tetrac with BSA 
concentrations in the incubation medium as indicated. The product of 
[“‘I]Td metabolism was identified by HPLC as Ts, and that of 
[“‘IlTetrac metabolism was identified as Triac. 
Gq- 0.5 
I-- 
0 1 2 3 4 5 
Time (h) 
FIG. 4. Effects of unlabeled Triac or Tetrac on the uptake of [12511Ts 
in cultured anterior pituitary cells. Cells were cultured and the ex- 
periment was performed as described in Fig. 2, except that the in- 
cubation contained [“‘I]Ts (50,000 cpm) (A) without or with 10 pM 
Triac (0) or Tetrac (e). Data represent the mean 2 SE of three to six 
observations from two independent experiments. 
more Tetrac was bound to albumin than in the control sub- 
jects (Table 6). 
The changes in serum binding during NT1 (Table 6) re- 
sulted in remarkable changes in the free fractions of Triac and 
Tetrac in NT1 patients (Fig. 6). In control subjects (no. l-5), 
the free Triac fraction was approximately 0.04%, whereas 
that of Tetrac was 0.0011%. Similarly low values for the free 
fractions of Triac and Tetrac in normal serum have previ- 
ously been described (27). During NT1 (patients 6-111, the 
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FIG. 5 Effects of unlabeled Ts (A), rTs CO), or Tetrac (Q TAJ on the 
15-min uptake of [‘z511TZ in cultured anterior pituitary cells. Cells 
were cultured and uptake of [ 1z51]Ts was measured for 15 min as 
described in Fig. 2. Incubation was performed with [“‘IIT~ (50,000 
cpm) without or with unlabeled Ts, rTa, or Tetrac present in concen- 
trations of 1 nM to 10 pM. Eachpoint represents the mean 2 SE of six 
observations from two independent experiments. 
free Triac fraction increased 2- to B-fold, and that of Tetrac 
increased 2- to 12-fold. 
Discussion 
The present study shows that both [1z51]Tetrac and [1z511rT~ 
are taken up and metabolized in cultured anterior pituitary 
cells. In addition, Tetrac and its major metabolite Triac sig- 
nificantly reduced the TSH response to TRH at total hormone 
concentrations of 1 and 0.01 nM, respectively, whereas rTs 
and its metabolite 3,3’-TZ had to be added at total concen- 
trations of 1 PM and 100 nM, respectively, to obtain a sig- 
nificant reduction of the TRH-induced TSH release. 
Expressed as percent dose, the uptake of [1z511Tetrac and 
[1251]rTs was very low. That both tracers were taken up by 
pituitary cells was indicated by the 24-h incubation experi- 
ments. Around 15% of the cell-associated radioactivity was 
[1z51]Triac after incubation with [**511Tetrac, 6% of cell-asso- 
ciated radioactivity was [*z51]TZ after incubation with 
[1z51]rT3, and 15-20% of cell-associated radioactivity was 
[1251]Ts after incubation with [*z51]Td. The deiodination of 
[*251]Th was almost completely blocked by simultaneous in- 
cubation with 1 PM unlabeled Te, but not by 100 pM I’TU. 
[‘*‘IITs was not metabolized in pituitary cells. Together, 
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TABLE 3. Effects of Tetrac, rTs, and Triac on TSH release from 
anterior pituitary cells during short term exposure to TRH 
Exp conditions TSH release Stimulation bid (%I 
Controls (23) 3.15 ? 0.22 
+ 100 nM TRH (25) 5.95 I! 0.14 +8ga 
TRH + 1 nM Tetrac (3) 
TRH + 10 nM Tetrac (6) 
TRH + 100 nM Tetrac (3) 
TRH + 1 ,uM Tetrac (9) 
4.87 5 0.26 +55b 
4.82 2 0.32 +53b 
4.09 k 0.39 +3ob 
3.73 2 0.19 + lBb 
TRH + 1 nM rTs (3) 
TRH + 10 nM rTa (6) 
TRH + 100 nM rTs (3) 
TRH + 1 PM rTs (6) 
5.22 k 0.64 +66 
5.29 k 0.18 +68 
4.93 ? 0.43 +57 
4.50 2 0.11 +43b 
TRH + 0.01 nM Triac (3) 4.06 ? 0.35 +29b 
TRH + 0.1 I-IM Triac (3) 3.83 k 0.25 +22b 
TRH + 1 nM Triac (3) 3.40 k 0.26 i-Bb 
TRH + 10 nM Triac (9) 3.10 2 0.19 -2b 
TRH + 100 nM Triac (6) 3.43 k 0.26 +gb 
TRH + 1 PM Triac (6) 2.90 k 0.17 -Bb 
Data indicate the mean of four experiments, with the number of 
observations inpore&/zeses. Each experiment included at least two of 
the tested compounds at comparable concentrations. Anterior pitu- 
itary cells were cultured for 3 days at a density of 500,000 cells/well. 
The cells were preincubated for 2 h in the absence or presence of 
Tetrac, rTs, or Triac at concentrations of 0.1 nM to 1 FM. Then, they 
were incubated with TRH (100 nM) for 2 h without or with the ad- 
ditions indicated. TSH was measured by RIA. 
a p < 0.05 us. controls. 
‘P < 0.05 vs. TRH alone. 
TABLE 4. Comparison of the effects of Tetrac and T* on TSH 
release during short term exposure to TRH 
Exp conditions TSH release hd 
Stimulation 
(%I 
Controls (6) 
+ 100 nM TRH (6) 
TRH + 100 nM Tetrac (3) 
TRH + 1 Tetrac (3) @M 
TRH + 10 nM Td (3) 
TRH + 100 niv T.. (3) 
2.50 k 0.49 
5.93 I!z 0.30 +137a 
4.09 2 0.39 +64b 
3.60 2 0.41 +44b 
4.33 2 0.48 +73b 
4.30 2 0.19 +72b 
Data indicate the mean 2 SE of three to six observations in a single 
experiment as indicated inpctrentheses. Anterior pituitary cells were 
cultured at a density of 500,000 cells/well. The experiment was per- 
formed as described in Table 3. 
a p < 0.05 us. controls. 
’ &’ < 0.05 ZJS. TRH alone. 
these results indicated the presence of type II deiodinase 
activity in the cultured anterior pituitary cells (19). 
Because of the low tracer uptake of [iz51]rT~ and [iz51]Tet- 
rat, it was impossible to test the effects of metabolic inhibitors 
and thyroid hormone analogs on the transport process. 
Therefore, we tested the effects of rTa and Tetrac on the 
uptake of [iz51]Tz. Neither rTa nor Tetrac had an effect on the 
15-min uptake of [lz51]Ta when added at concentrations of 
l-100 nM, and both showed a significant reduction of [iz51]Ts 
uptake (45%) at a concentration of 1 /AM. In a previous study, 
the presence of 10 PM rTa reduced the 15-min uptake of 
[iz51]Td by 32%, whereas 10 ,uM Tetrac had no effect (23). As 
Ta and TJ probably share the same transport mechanism in 
TABLE 5. Comparison of the effects of 3,3’-Tc, 3,5-Ta, and Ts on 
TSH release from cultured anterior pituitary cells during short 
term exposure to TRH 
Exp conditions 
Controls (21) 
+ 100 no TRH (21) 
TRH + 0.1 nM 3,3’-Ta (6) 
TRH + 1 niv 3>3’-Tz (9) 
TRH + 10 nM 3,3’-Ta (9) 
TRH + 100 nM 3,3’-Ta (9) 
TRH + 0.1 nM Ts (5) 
TRH + 1 nM Ta (9) 
TRH + 10 nM Ts (8) 
TRH + 100 nM Ts (9) 
TSH release 
bgl 
2.78 5 0.41 
6.48 2 0.45 
5.45 2 0.36 
4.84 ? 0.43 
5.52 k 0.24 
3.98 k 0.29 
6.27 2 0.52 
4.04 5 0.52 
3.49 5 0.44 
3.10 2 0.26 
Stimulation 
(%I 
+ 133a 
+96 
i74 
+98 
+43h 
+125 
+45b 
+26b 
+ 12b 
TRH + 0.1 nM 3,5-Ta (6) 5.14 2 0.35 +85 
TRH + 1 no 3,5-Ta (9) 4.52 2 0.28 +63b 
TRH + 10 nM 3,5-Ta (9) 4.47 k 0.26 +61b 
TRH + 100 niv 3,5-Ta (9) 4.03 ?c 0.36 +45b 
Data indicate the mean 2 SE ofthree experiments, with the number 
of observations inparentheses. Anterior pituitary cells were cultured 
at a density of 500,000 cells/well. Experiments were performed as 
described in Table 3. 
a P < 0.05 vs. controls. 
‘P < 0.05 us. TRH alone. 
the pituitary (23,28), one might expect that uptakes of Ta and 
T4 are equally inhibited by analogs. 
The results obtained in the present and our previous study 
(23) do not argue against the possibility that rTa is taken up 
by the same transporter involved with Ta and Tb uptake. The 
conclusion for Tetrac is more complicated. The uptake of 
Tetrac per picomolar concentration of free hormone (-1 
fmol) was as high as that of Triac (11). Furthermore, 10 FM 
Tetrac reduced the uptake of ]*z51]T3 (15 min to 4 h) to the 
same extent as 10 PM Triac. In our study of ]1z51]Triac uptake 
(11), it was concluded that at least part of Triac entered the 
pituitary by a mechanism different from the T3 transporter. 
Together, the similarities between Tetrac and Triac suggest 
that Tetrac enters the pituitary in the same way as Triac, i.e. 
at least partly by another mechanism than the Ta/Td trans- 
porter. 
Tetrac was effective in reducing the TSH response to TRH 
at a total concentration of 1 nM, i.e. at a free concentration of 
0.05 PM. 100 nM Tetrac showed the same inhibitory effect as 
IO nM Ta or 0.01 nM Triac. Corrected for the difference in free 
fraction in medium with 0.5% BSA (Tetrac, 0.005%; T*, 0.5%; 
Triac, 0.5%), 5 PM Tetrac was thus as effective as 50 PM T.+ or 
0.05 PM Triac. In a direct comparison between Triac and Ta, 
it was estimated that Triac was 8 times more effective than 
Ta in reducing the TSH response to TRH (11). Thus, the order 
of potency for reducing TSH release in pituitary cells seems 
to be Triac > Ts > Tetrac > T+ 
The question remains of whether the effect of Tetrac or TJ 
on TSH release during 4 h of incubation is due to a direct 
effect or to an effect of their respective metabolites Triac and 
Ts. In a previous study on the metabolism of [iz51]Ta, it was 
found that iodide production into the medium after 6 h of 
incubation was about 40% of that found after 24 h (23). 
Assuming a similar value for Tetrac, and that a proportion- 
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TABLE 6. Distribution of Triac and Tetrac between serum proteins in control subjects and NT1 patients 
Triac (%) Tetrac (%) 
Subject no. 
TBG Albumin TBPA TBG Albumin TBPA 
Control 1 2.9 43.3 53.0 1.8 5.9 88.7 
Control 2 0 49.9 48.6 2.4 6.1 89.2 
Control 3 0 48.6 49.6 3.6 4.9 89.2 
Control 4 0 45.5 53.3 7.7 5.6 85.6 
Mean 2 SE 0.7 2 0.7 46.8 2 1.5 51.1 k 1.2 3.9 2 1.3 5.6 k 0.3 88.2 2 0.9 
NT1 7 0 59.0 39.7 3.0 6.2 89.2 
NT1 8 0 54.1 44.8 4.3 9.2 85.7 
NT1 9 1.0 68.6 29.7 2.6 10.5 83.2 
NT1 11 2.0 64.3 33.3 3.8 10.5 81.2 
Mean 2 SE 0.8 2 0.5 61.5 k 3.Za 36.9 k 3.4” 3.4 2 0.4 9.1 k 1.0* 84.8 k 1.7 
Data present individual values and the mean 2 SE of four healthy control subjects (no. l-4) and four patients with NT1 (no. 7-9, 11). The 
distribution of Triac and Tetrac among serum proteins was determined by agar gel electrophoresis. 
a E’ < 0.005. NT1 U.S. control subjects. 
bP < 0.025, NT1 W. control subjects. 
0 Triw - Teirac 
o.4 - O.O.2 
1 2 3 4 5.6 
CONTROL ” NT1 
FIG. 6. Free fraction of Triac (U; kfi y-axis) and Tetrac W; right 
y-axis) in serum obtained from five healthy control subjects (no. l-5) 
and six patients with NT1 (no.6-11). The free fractions were deter- 
mined in duplicate by equilibrium analysis. 
ally lower amount of J iz511Triac is formed after 6 h of incu- 
bation (-5%; i.e. 40% of 15% [*z51]Triac), this would mean 
that 10 nM Tetrac (in a volume of 0.5 ml = 5 pm011 with an 
uptake of 0.2% results in 0.5 fmol intracellular Triac within 
6 h. Furthermore, 0.1 nM Triac (in a volume of 0.5 ml = 50 
fmol), with an uptake of 1% (11) would result in 0.5 fmol 
intracellular Triac. As the effect of 10 nM Tetrac on TRH- 
induced TSH release was similar to that of 0.1 nM Triac, the 
effect of Tetrac on TRH-induced TSH release can be the result 
of its deiodination to Triac. 
rTa was only effective at a total concentration of 1 PM, 
whereas its metabolite 3,3’-Tz induced a significant reduction 
in TRH-stimulated TSH release at a total concentration of 100 
niw In contrast, the Ta metabolite 3,5-Tz, showed a significant 
effect on TSH release at a concentration of 1 nM and was 
about loo-fold less effective than Ta. Thus, 3,5-Tz seems to be 
more effective in reducing TSH release than 3,3’-T?, whereas 
the two diiodothyronines were equally effective in stimula- 
tion of the mitochondrial respiratory rate (16). However, our 
results support the in vivo observations in rats, in which 
3,5-Tz reduced TSH secretion at doses lo- to loo-fold higher 
than those of Ts (18). 
The question of whether rTa or its metabolite 3,3’-Tz play 
a role in inhibition of TSH secretion during NT1 can be 
addressed as follows: the normal total serum levels of rTa and 
3,3’-Tz are 0.40 and 0.11 nM (29). The same study showed that 
the serum total rTs concentration during NT1 rose to 0.66 nM, 
whereas that of 3,3’-Tz declined to 0.05 nM. This should be 
compared with the total hormone concentrations resulting in 
significant effects iyz vitro, i.e. 1 FM rTa and 100 nM 3,3’-Tz, 
respectively, in a medium containing 0.5% BSA where the 
free fraction will be at least lo-fold greater than that in serum. 
The difference between the effective concentrations jx vitro 
and those present in vivo is thus at least a factor of 10,000, 
which is not in favor of any biological significance of the two 
compounds in viva. The small inhibitory effect of rTa on 
TRH-induced TSH release cannot solely be explained by the 
low uptake of rTs by pituitary cells; compared with Ta, a 
lOOO-fold higher total concentration of rTa was required to 
reduce TSH release to the same extent (1 FM rTs vs. 1 nM Ta). 
In terms of free concentration, the difference will be a factor 
of 500 (free Ta fraction, 3.8%; free rTa fraction, 1.9%), whereas 
the difference in cellular uptake was a factor of 10. 
The normal total serum Tetrac concentration varies be- 
tween 0.7 nM (15) and 1.3 nM (13), With a free fraction of 
O.OOll%, the free Tetrac concentration in normal serum will 
be around 0.011 PM. As the production rate increases Z-fold 
in fasting (15) and the mean free fraction increases 7-fold 
during NTI, the resulting free concentration during fasting or 
NT1 will be about 0.15 PM. The lowest Tetrac concentration 
tested that reduced the response to TRH significantly was 1 
nM, i.e. a free Tetrac concentration of 0.05 PM, which is of 
same order of magnitude as the free concentrations occurring 
in vivo. 
Just as postulated for Triac, the low serum Tetrac concen- 
tration may be the result of the very effective glucuronidation 
in the liver (30). Although the free concentration of Tetrac in 
serum (0.01-0.15 PM; see above) is lower than that of Triac 
(0.02-0.3 PM; estimated from Refs. 9,11, and 31), Ta (2-4 PM) 
(3), or TJ (18-25 PM) (l-3), it is not excluded that Tetrac 
contributes to TSH suppression during NTI, because its up- 
take (per picomolar concentration of free hormone) into the 
pituitary is much larger than that of Ta and Th, whereas it is 
more effective than Td in reducing the TSH response to TRH. 
Also, the tentative conclusion that Tetrac (and Triac) are at 
least partly taken up in the pituitary by other transport mech- 
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anisms than Ts and T4 would support a possible role of the 
compound in vjvo. 
The large rise in the estimated free concentrations of Tetrac 
and Triac in patients with NT1 is not only due to the increase 
in the production rate (possibly 2- to 3-fold) (9, 151, but also 
to the rise in free fraction (2- to 12-fold; this study). The latter 
seems due to the fact that the level of TBPA, the most im- 
portant binding protein for the two compounds in serum, 
strongly decreases during illness (101, 
The conclusion of our study is that Tetrac and rTs, the 
serum concentration of which increases during fasting and 
NTI, are taken up and metabolized in cultured anterior pi- 
tuitary cells. Only Tetrac reduces the TSH response to TRH 
jti vjfyo at concentrations comparable to those estimated Gz 
vjvo. Because Tetrac probably enters the pituitary through 
another transport system such as that described for Ts and 
T4, our results do not exclude a potential role for Tetrac in the 
inappropriately low serum TSH observed during NTI. 
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